Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a new class of DNA Damage Response (DDR) therapies with its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DDR therapy market that is distinct from established PARP inhibitor therapies.
The company holds five patents protecting its PNKP inhibitor technology, nanoparticle delivery platform, and related applications, supporting its intellectual property position as development advances. Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph causal AI platform to support patient stratification, clinical trial design, and oncology evidence generation.
Ongoing CMC, IND-enabling, and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies. The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations, and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions and research partnerships.
This news matters because Onco-Innovations is targeting a key mechanism of cancer resistance: DNA repair. By inhibiting PNKP, the company aims to disrupt the repair of DNA damage in cancer cells, potentially making tumors more susceptible to treatment. The nanoparticle delivery system could enhance drug delivery and reduce side effects compared to traditional therapies.
The integration of AI through Inka Health’s SynoGraph platform adds a precision medicine dimension, enabling better patient selection and trial design. This could accelerate development and increase the likelihood of clinical success. For patients, this could mean more effective treatments with fewer side effects. For the oncology industry, it represents a potential new class of drugs that may overcome resistance to existing therapies like PARP inhibitors.
Investors should note that Onco-Innovations is a clinical-stage company, and its candidates are still in preclinical development. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
This press release was disseminated on behalf of Onco-Innovations Ltd. and may include paid advertising. InvestorWire (IW) is a specialized communications platform focused on advanced wire-grade press release syndication. More information is available at https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
